Eric Schmidt
2018
In 2018, Eric Schmidt earned a total compensation of $2.6M as Chief Financial Officer at Allogene Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $88,099 |
|---|---|
| Option Awards | $2,299,658 |
| Salary | $201,232 |
| Total | $2,588,989 |
Schmidt received $2.3M in option awards, accounting for 89% of the total pay in 2018.
Schmidt also received $88.1K in non-equity incentive plan and $201.2K in salary.
Rankings
In 2018, Eric Schmidt's compensation ranked 4,519th out of 14,244 executives tracked by ExecPay. In other words, Schmidt earned more than 68.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,519 out of 14,244 | 68th |
Division Manufacturing | 1,694 out of 5,765 | 71st |
Major group Chemicals And Allied Products | 610 out of 2,128 | 71st |
Industry group Drugs | 510 out of 1,817 | 72nd |
Industry Biological Products, Except Diagnostic Substances | 100 out of 339 | 71st |
Source: SEC filing on April 24, 2019.
Schmidt's colleagues
We found three more compensation records of executives who worked with Eric Schmidt at Allogene Therapeutics in 2018.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Allogene Therapeutics CEO David Chang receives $13M in 2018
April 24, 2019